PXD016005

PXD016005 is an original dataset announced via ProteomeXchange.

Title	U2OS LC MSMS upon siRNA-eIF4A3 or 5nM ActD treatment.
Description	Proteome analysis in U2OS cells treated with siRNA against eIf4A3 or 5nM Actinomycin D.
HostingRepository	PRIDE
AnnounceDate	2021-09-08
AnnouncementXML	Submission_2021-09-08_11:45:41.768.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Dimitrios Kanellis
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	TMT6plex-126 reporter+balance reagent acylated residue; monohydroxylated residue; iodoacetamide derivatized residue
Instrument	Q Exactive

Revision	Datetime	Status	ChangeLog Entry
0	2019-10-24 06:32:15	ID requested
⏵ 1	2021-09-08 11:45:42	announced

Kanellis DC, Espinoza JA, Zisi A, Sakkas E, Bartkova J, Katsori AM, Bostr, ö, m J, Dyrskj, ø, t L, Broholm H, Altun M, Els, ä, sser SJ, Lindstr, ö, m MS, Bartek J, The exon-junction complex helicase eIF4A3 controls cell fate via coordinated regulation of ribosome biogenesis and translational output. Sci Adv, 7(32):(2021) [pubmed]

submitter keyword: U2OS LC MSMS upon siRNA-eIF4A3 or 5nM ActD treatment.

Jiri Bartek
contact affiliation	Danish Cancer Society Karolinska Institute
contact email	jb@cancer.dk
lab head
Dimitrios Kanellis
contact affiliation	SciLifeLab & Karolinska Institutet
contact email	dimitrios.kanellis@scilifelab.se
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD016005

PRIDE project URI

• PRIDE
  1. PXD016005
     1. Label: PRIDE project
     2. Name: U2OS LC MSMS upon siRNA-eIF4A3 or 5nM ActD treatment.